Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib, Rituximab, and Methotrexate in First-line PCNSL
NCT06454266Phase 2Completed
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Dec 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by First Affiliated Hospital of Ningbo University. Started Dec 2021; status: completed.
02
Drugs
orelabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06454266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454266.